肿瘤分子靶向治疗的进展及问题

被引：23

作者：

储大同

机构：

[1] 中国医学科学院肿瘤医院

来源：

临床肿瘤学杂志 | 2006年 / 01期

关键词：

肿瘤; 分子靶向治疗; 研究进展;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

摘要：

引用

页码：1 / 6

页数：6

共 9 条

[1]

RandomizedphaseⅡ/Ⅲtrialofpaclitaxel(P)pluscarboplatin(C)withorwithout bevacizumabinpatientswithadvancednon squamousnon small celllungcancer(NSCLC):AnEasternCooperativeOncology Group(ECOG)trial E4599. SandlerAB,GrayR,BrahmerJ,etal. ProAmSocClinOncol . 2005

[2]

Insulin likegrowthfactor1receptorenhancesinvasionandinducesresistancetoapoptosisof coloncancercellsthroughtheAkt/Bcl x(L)pathway. SekharamM,ZhaoH,SunM,etal. Canc erRes . 2003

[3]

PhaseIItrialofbevacizumabanderlotinibinpatientswithmetastaticrenalcarci noma(RCC). HainsworthJD,SosmanJA,SpigelDR,etal. ProcAmSocClinOncol . 2004

[4]

ActivationofFasreceptor modulatescytochromeP4503A4expressioninhumancoloncar cinomacells. ChunYJ,ParkS,YangSA,etal. Toxicology Letters . 2003

[5]

Inhibitionofprimary coloncarcinomagrowthandlivermetastasisbytheA3adenosine receptoragonistCF101. OhanaG,Bar YehudaS,ArichA,etal. British Journal of Cancer . 2003

[6]

HER2receptorexpression,localization,andactivationincolorectalcancercell linesandhumantumors. HalfE,BroaddusR,DanenbergKD,etal. International Journal of Cancer . 2004

[7]

SU011248,anovel tyrosinekinaseinhibitor,showsantitumoractivityinsecond line therapyforpatientswithmetastaticrenalcellcarcinoma:results ofaphase2trial. MotzerRJ,RiniBI,MichaelsonMD,etal. ProcAmSocClinOncol . 2004

[8]

Durableremissionsaf territuximabplusthalidomideforrelapsed/refractorymantlecell lymphoma. DrachJ,KaufmannH,WoehrerS,etal. ProcAmSocClinOncol . 2004

[9]

High dosebev acizumabimprovessurvivalwhencombinedwithFOLFOX4in previouslytreatedadvancedcolorectalcancer:Resultsfromthe EasternCooperativeOncologyGroup(ECOG)studyE3200. GiantonioBJ,CatalanoPJ,MeropolNJ,etal. ProAmSocClinOncol . 2005

← 1 →